T. Rowe Price Associates
ELV icon

T. Rowe Price Associates’s Elevance Health ELV Stock Holding History

T. Rowe Price Associates’s Portfolio ELV Stock Details ELV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-58,000
Closed -$5.36M – 2503
2013
Q4 		$5.36M Buy
+58,000
New +$5.15M ﹤0.01% 1420

Other funds holding ELV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Sanders Capital
Sanders Capital West Palm Beach, Florida $99.8B AUM 47.9% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

T. Rowe Price Associates's ELV Position: Q2 2026 in Review

T. Rowe Price Associates reduced its Elevance Health (ELV) stake by 15% in Q2 2026, selling an estimated $271M and leaving 4,014,991 shares worth $1.55B. The position accounts for 0.16% of the portfolio, ranked #119.

T. Rowe Price Associates first reported a position in ELV in Q2 2013 and has held it in 53 quarters since. The position peaked at $6.53B in Q4 2022. 1,611 funds tracked by Wall St. Rank hold ELV as of Q2 2026.

  • T. Rowe Price Associates held 4,014,991 shares of Elevance Health worth $1.55B as of Q2 2026.
  • T. Rowe Price Associates sold 731,594 Elevance Health shares in Q2 2026, an estimated $271M.
  • Elevance Health made up 0.16% of T. Rowe Price Associates's portfolio in Q2 2026, its #119 holding.
  • T. Rowe Price Associates first reported a position in Elevance Health in Q2 2013 and has held it in 53 quarters since.
  • T. Rowe Price Associates's Elevance Health position peaked at $6.53B in Q4 2022.
  • 1,611 funds tracked by Wall St. Rank held Elevance Health as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.